LUCERNE
E822410
LUCERNE is a large phase III clinical trial evaluating the efficacy and safety of faricimab for the treatment of neovascular (wet) age-related macular degeneration.
Statements (13)
| Predicate | Object |
|---|---|
| instanceOf |
clinical trial
ⓘ
phase III clinical trial ⓘ |
| evaluates |
efficacy of faricimab
ⓘ
faricimab NERFINISHED ⓘ safety of faricimab ⓘ |
| hasConditionCategory |
age-related macular degeneration
GENERATED
ⓘ
retinal disease GENERATED ⓘ |
| hasPhase | Phase III ⓘ |
| hasPrimaryIndication |
neovascular age-related macular degeneration
ⓘ
wet age-related macular degeneration ⓘ |
| hasTherapeuticArea | ophthalmology ⓘ |
| studies | treatment of neovascular (wet) age-related macular degeneration ⓘ |
| usesIntervention | faricimab ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.